Last edited by Nisar
Saturday, May 16, 2020 | History

2 edition of Orally active antitumour agents, patient compliance and clinical trials. found in the catalog.

Orally active antitumour agents, patient compliance and clinical trials.

Peter Clement Secrett

Orally active antitumour agents, patient compliance and clinical trials.

by Peter Clement Secrett

  • 351 Want to read
  • 6 Currently reading

Published by Aston University Department of Pharmaceutical Sciences in Birmingham .
Written in English


Edition Notes

Thesis (MPhil) - Aston University 1988.

ID Numbers
Open LibraryOL13876607M

Background: The use of oral medications in cancer treatment has increased considerably the past several years with the ongoing development of novel oral anticancer gh the rapid implementation of oral anticancer agents into practice has been widely adapted, there are numerous opportunities to improve quality in the prescribing and monitoring of patients receiving oral anticancer.   Clinical Trials Show Direct Oral Anticoagulants Are Safe, Effective for Cancer-Related Venous Thromboembolism. Direct oral anticoagulants are safe and effective for most patients with cancer-associated venous thromboembolism. Here are recommendations about when to use them instead of low-molecular-weight heparin.

Cannabis, also known as marijuana, originated in Central Asia but is grown worldwide the United States, it is a controlled substance and is classified as a Schedule I agent (a drug with a high potential for abuse, and no currently accepted medical use). The Cannabis plant produces a resin containing psychoactive compounds called cannabinoids, in addition to other compounds found in. Based Clinical Practice Guidelines in this supplement. Results: Most practical clinical questions regarding the management of anticoagulation, both oral and parenteral, have not been adequately addressed by randomized trials. We found suffi cient evidence for summaries of recommendations for 23 questions, of which only two are strong rather.

Phase III clinical trials for the new agents demonstrated that dabigatran (RE-LY, ) and apixaban (ARISTOTLE, ) were more efficacious at preventing stroke in non-valvular atrial fibrillation than warfarin, 7,8 while rivaroxaban (ROCKET-AF, ) was shown to be non-inferior to warfarin. 9 A meta-analysis of these three trials. View This Abstract Online; The new oral anticoagulants: a challenge for hospital formularies. Hosp Pract (). ; 40(3) (ISSN: ). Merli GJ. Introduction Over the past 60 years, clinicians have used vitamin K antagonists, primarily warfarin, as the sole oral anticoagulants for managing a variety of thrombotic disorders.


Share this book
You might also like
Remaines concerning Britaine: but especially England, and the inhabitants thereof

Remaines concerning Britaine: but especially England, and the inhabitants thereof

nature of the present excise

nature of the present excise

Bakers white letter direct etching and embossing processes.

Bakers white letter direct etching and embossing processes.

Gunga Din

Gunga Din

Recent advances in matrix theory

Recent advances in matrix theory

Proceedings of the 21st IEEE International Conference on Software Maintenance.

Proceedings of the 21st IEEE International Conference on Software Maintenance.

Assessment of geochemical variability and a listing of geochemical data for soils, drain sediments, alfalfa, greasewood, groundwater and water extractable soil constituents from the TJ-Drain study area, Nevada

Assessment of geochemical variability and a listing of geochemical data for soils, drain sediments, alfalfa, greasewood, groundwater and water extractable soil constituents from the TJ-Drain study area, Nevada

Neo-feudalism : the Canadian dilemma

Neo-feudalism : the Canadian dilemma

Japan--economic development and foreign policy

Japan--economic development and foreign policy

A pastoral letter to the Catholic clergy of the united diocesses of Waterford and Lismore

A pastoral letter to the Catholic clergy of the united diocesses of Waterford and Lismore

Message of the President

Message of the President

Canada Prenatal Nutrition Program celebrates 10 years

Canada Prenatal Nutrition Program celebrates 10 years

Impact Of The Presidents Veto Of The Fiscal Year 1996 VA-HUD,... Hearing... S.HRG. 104-452... Committee On Appropriations, U.S. Senate... 104th Congress, 2nd Session.

Impact Of The Presidents Veto Of The Fiscal Year 1996 VA-HUD,... Hearing... S.HRG. 104-452... Committee On Appropriations, U.S. Senate... 104th Congress, 2nd Session.

Orally active antitumour agents, patient compliance and clinical trials by Peter Clement Secrett Download PDF EPUB FB2

A compliance questionnaire was conducted to collect the compliance of the drug during treatment. According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.

Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Background: In oral agent clinical trials, patients may not be adherent to self-administration of study medication; this nonadherence can affect validity and reliability.

Many factors contribute to nonadherence to protocol requirements, and managing patients with fidelity issues is the responsibility of the research team.

Among numerous new anticoagulant agents being in clinical development, the orally active direct inhibitors of activated factor Xa (FXa), rivaroxaban and apixaban, and the orally active direct inhibitor of thrombin, dabigatran, are in the most advanced stage of clinical development–23 Apixaban, rivaroxaban, and dabigatran have been approved Cited by: Patient compliance and clinical trials.

book numerous new anticoagulant agents being in clinical development, the orally active direct inhibitors of activated factor Xa (FXa), rivaroxaban and apixaban, and the orally active direct inhibitor of thrombin, dabigatran, are in the most advanced stage of clinical development.

19–23 Apixaban, rivaroxaban, and dabigatran have been. Generally, therapy discontinuation is driven by a clinical reason (for instance, bleeding), or is explained by patient non-compliance or non-adherence.

The average rate of VKA therapy discontinuation has been reported 30% during first year, and up to 50% within 3 years following treatment by: New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients Grigoris T Gerotziafas,1,2 Isabelle Mahé,3 Ismail Elalamy1,21Service d'Hématologie Biologique, Hôpital Tenon, Hôpitaux Universitaires Est Parisien Assistance Publique Hôpitaux de Paris, Paris, France; 2ER2UPMC, Faculté de Médecine Pierre et Marie Curie.

Evaluation in Various Clinical Trials New oral anticoagulant drugs (NOADs) have been vigorously evaluated in various large-scale clinical trials. proach hospitals, outpatient clinics, and specific patient associations or organizations.

As datawere collected anonymously, viathe online ques-tionnaire, it was impossible to identify the patient.

Each patient was asked to enter their individual dataviathe internet without any interfer-ence from medical staff. The study was conducted from Clinical trials are used to test and develop new treatments.

The goal of these trials is to find ways to improve cancer treatment. While a trial or study is active or in progress we will not know whether –there may be a potential benefit to you. The trial must be closed and the data analyzed before theFile Size: KB. People on oral anticoagulants need regular monitoring of INR.

INR is checked daily until in the therapeutic range, twice a week for weeks, weekly until stable, then every weeks. Change in a patient's condition - eg, liver disease, intercurrent illness, a new drug started - Author: Dr Colin Tidy.

The drugs include rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Lixiana), and betrixaban (Bevyxxa). Of note, the generic names for these agents all end in “Xa-ban.” 5.

Recommendations for each agent are based largely on the efficacy and safety in. Oral Adherence Toolkit Tool 1. Patient Assessment Checklist Tool 2. Patient Education Tool 3. Oral Chemotherapy Ordering Standards Tool 4. Pharmacy Descriptions, Benefits, and Concerns Tool 5.

Reimbursement and Patient Assistance Resources Tool 6. Food, Drug and Pathway Interactions and Effects Tool 7. Sample Treatment Calendars Tool 8.

Approximately 25% to 30% of all new drugs for cancer in development are oral agents. This represents a paradigm shift in oncology patient care and practice changes. Consequently, in the absence of head-to-head trials, it is impossible to say that one drug is better than another.

Until such trials are done, therefore, it is likely that the unique pharmacologic properties and the differences among the agents that have arisen from the clinical trials will drive the decision as to which of the new agents to Cited by: ORAL chemotherapy and oral targeted therapy usage accounts for approximately 10% to 25% of all cancer treatment therapies.1, 2 Approximately new drugs in development will be orally administered as chemotherapy and targeted therapy agents.

3 Chemotherapy refers to chemicals that have a specific toxic effect on a disease-producing microorganism or that destroy cancerous tissues. 4 Targeted Cited by: 2. The only available orally active antileishmanial drug is miltefosine with long half life and teratogenic potential limits patient compliance.

Thus there is a genuine need for an orally active. SAN ANTONIO, Tex.–Instituting a Chemotherapy Safety Committee and developing an administration process successfully standardized the inpatient oral. emerging, because of the introduction of orally active tar- geted agents and the proven efficacy and convenience for patients, despite the main concerns of low complianc e and.

As these new agents are tested and released onto the market when deemed safe and effective, hopefully patient outcomes in acute coronary syndromes will continue to improve. References Roger VL, Go AL, Lloyd-Jones DM, et al., Heart Disease and Stroke Statistics – update, Circulation, ;e18–eAuthor: Suzanne J Baron, Robert P Giugliano.

How to choose appropriate direct oral anticoagulant for patient analysis provides an appraisal of the respective clinical trials and highlights much of what remains unknown about four FDA-approved agents: dabigatran, apixaban, rivaroxaban, or compliance concerns might do better with agents dosed once a day.

A summary of characteristics Cited by:   Interpretation: The results of this trial indicate that a strategy of routine continuation of DOACs for reducing pocket hematomas is not superior to one of interrupted DOAC use in the periprocedural period among patients with a high CHA 2 DS 2-VASc score who are on a DOAC and undergoing an EP trial was terminated early due to futility; it was powered for an event.

The direct-acting oral anticoagulants (DOACs) have been increasingly used over vitamin K antagonists in recent years because they do not require monitoring and have an immediate anticoagulation effect. In general, DOACs have exhibited a better safety profile and noninferiority for prophylaxis and treatment of venous thromboembolism (VTE) and stroke prevention in patients with Author: Parth Rali, Andrew Gangemi, Aimee Moores, Kerry Mohrien, Lisa Moores.